A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease

Official title

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease

Overview

This is a randomized, double-blind phase I clinical trial to evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AK152 in Healthy Volunteers and Patients with Alzheimer' s Disease.

Detailed description

This is a randomized, double-blind phase I clinical trial to evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AK152 in Healthy Volunteers and Patients with Alzheimer' s Disease. Subjects will be randomized to receive AK152 regimen or placebo treatment.

Interventions

• Drug AK152
  Subjects receiving single or multiple doses of AK152 injection.
• Drug Placebo
  Subjects receiving single or multiple doses of placebo injection.

Primary outcome measures

• Adverse Events (AE) [Time frame: Up to approximately 8 weeks after the last dose]

Secondary outcome measures (5)

• Peak concentration (Cmax) [Time frame: Up to approximately 8 weeks after the last dose]
• Time to peak (Tmax) [Time frame: Up to approximately 8 weeks after the last dose]
• Area under the curve (AUC) [Time frame: Up to approximately 8 weeks after the last dose]
• Half-life (t1/2) [Time frame: Up to approximately 8 weeks after the last dose]
• Immunogenicity characteristics of AK152 [Time frame: Up to approximately 8 weeks after the last dose]

Eligibility criteria

Key Inclusion Criteria - Part 1 (Healthy Volunteers):

• Healthy male or female subjects aged 18 to 40 years (inclusive) at the time of signing the informed consent form (ICF).
• Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; body mass index (BMI) = weight (kg) / height² (m²) within the range of 19.0-26.0 kg/m² (inclusive).
• Subjects agree to take protocol-specified contraception measures and refrain from donating sperm or oocytes from signing the ICF through the treatment period and for at least 90 days after the last administration of study drug; women of childbearing potential must be non-pregnant and non-lactating.
• Subjects are able to understand and voluntarily sign a written ICF before any study-specific procedures are performed, and are able to comply with the study procedures and follow-up requirements.

Key Exclusion Criteria - Part 1 (Healthy Volunteers):

• Known allergy to components of AK152 injection or any monoclonal antibody, or high risk of allergy.
• History or presence of any systemic disease that may interfere with study results.
• Clinically significant abnormalities in vital signs at screening or prior to randomization.
• Clinically significant laboratory abnormalities at screening or prior to randomization per investigator judgment.
• Use of any medication (including prescription, OTC, herbal medicines, dietary supplements) within 4 weeks before randomization or within 5 half-lives of the medication (whichever is longer), or planned use during the study.
• History of frequent alcohol consumption within 24 weeks or inability to abstain during inpatient stay.
• Drug abuse or positive urine drug screen at screening.
• Smokers consuming >5 cigarettes/day within 12 weeks prior to screening or unable to abstain during the inpatient period.
• Excessive intake of tea, coffee, or other caffeine-containing beverages.

Key Inclusion Criteria - Part 2 (Alzheimer' s Disease Patients):

• Able to understand and voluntarily sign a written ICF before any study-specific procedures are performed, and able to comply with study procedures and follow-up requirements.
• Aged 50 to 85 years (inclusive) at the time of signing the ICF.
• BMI within 17.0-35.0 kg/m² (inclusive).
• Subjects agree to take protocol-specified contraception measures and refrain from donating sperm or oocytes from signing the ICF through the treatment period and for at least 90 days after the last dose; women must be non-pregnant and non-lactating.
• The subject must have an identified trial partner who must sign a separate ICF.
• Meets the 2011 NIA-AA core clinical criteria for MCI due to AD or mild AD dementia.
• Evidence of brain amyloid deposition confirmed by Aβ-PET/CT at screening.

Key Exclusion Criteria - Part 2 (Alzheimer' s Disease Patients):

• History or evidence of malignancy involving any organ system within 5 years prior to screening, regardless of treatment or remission status (except completely cured carcinoma in situ of the cervix, non-metastatic squamous cell carcinoma of the skin, or basal cell carcinoma).
• Severe or unstable disease at screening or prior to randomization that may affect study assessments.
• Major neurological disorder (other than AD) that may affect cognition or ability to complete study procedures.
• Transient ischemic attack (TIA) or stroke within 12 months prior to randomization.
• Clinically significant abnormalities on brain MRI at screening.
• Known allergy to components of AK152 injection or any monoclonal antibody, or high risk of allergy.
• History of alcohol or drug abuse within 2 years prior to screening or prior to randomization.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Treatment

Study locations

China · 1 center

• The Frist Affiliated Hospital of USTC — Hefei

Identifiers

NCT: NCT07301502 · AK152-101

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗